The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity

CAR T-cell therapy is well tolerated and effective in patients with Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). However, even second- generation anti-CD30 CAR T-cells with CD28 (28z) costimulatory domains failed to achieve the desired rate of complete responses. In the present s...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shangkun, Gu, Chaojiang, Huang, Lifang, Wu, Han, Shi, Jiangzhou, Zhang, Zijian, Zhou, Yong, Zhou, Jingjiao, Gao, Yang, Liu, Jiaxing, Leng, Yingqi, Liu, Xiyu, Zhang, Qinxing, Huang, Liang, Tong, Xiqin, Young, Ken H., Li, Jiapeng, Zhu, Haichuan, Zhang, Tongcun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213494/
https://www.ncbi.nlm.nih.gov/pubmed/35729339
http://dx.doi.org/10.1038/s41598-022-14523-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213494/
https://www.ncbi.nlm.nih.gov/pubmed/35729339
http://dx.doi.org/10.1038/s41598-022-14523-0

Ejemplares similares